Latest1 information on COVID-19

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Not Recruiting

Trial ID: NCT01617954

Age - 18 Years-90 Years Condition - Breast Cancer Gender - Female Accepting Healthy Volunteers - No

Purpose

This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Official Title

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Stanford Investigator(s)

Mark Pegram

Susy Yuan-Huey Hung Professor

Kristin Jensen

Eligibility


Inclusion Criteria:

   - Women with histologically proven invasive stage I-II, node negative, hormone receptor
   positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score
   (18-30)

   - ≥ 18 years of age at time of consent

   - Written informed consent

Exclusion Criteria:

   - Insufficient tissue remaining for Mammaprint FFPE

   - Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria

   - Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy

View More
View Less

Intervention(s):

device: MammaPrint

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Annabel Castaneda
650-498-7977

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine